Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
KAT6 is an emerging target in hormone sensitive breast tumors and other cancers.Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer - the most common subtype.The molecule has demonstrated strong
San Antonio United States Elcin Barker Ergun Alex Zhavoronkov Stemline Therapeutics Inc Menarini Group
Source: newswit.com